# Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Clinical trial · Hunan Province Tumor Hospital

- Archive id: nct:NCT05055908
- Published: 2021-09-24
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05055908
- Source URL: https://clinicaltrials.gov/study/NCT05055908
- Provenance: clinicaltrials

## Abstract

The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: BECOME
- status: RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 12000
- sponsor: Hunan Province Tumor Hospital
- conditions: Lung Cancer
- interventions: DRUG: Pemetrexed plus Pembrolizumab; DRUG: Pembrolizumab; DRUG: Pemetrexed
- start date: 2021-10-01
- start date type: ACTUAL
- primary completion date: 2025-07-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.